EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Recursion Pharmaceuticals, Inc. (RXRX) had EBIT Margin of -1297.85% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$14.74M |
|
$-202.49M |
|
$21.83M |
|
$-7.08M |
|
$206.11M |
|
$-191.37M |
|
$-11.28M |
|
$-202.65M |
|
$-202.65M |
|
$-202.49M |
|
$-202.49M |
|
$-202.49M |
|
$-202.49M |
|
$-191.37M |
|
$-172.04M |
|
402.77M |
|
402.77M |
|
$-0.50 |
|
$-0.50 |
|
| Balance Sheet Financials | |
$584.14M |
|
$126.83M |
|
$721.09M |
|
$1.31B |
|
$141.98M |
|
$16.45M |
|
$229.31M |
|
$371.29M |
|
$933.95M |
|
$440.05M |
|
$933.95M |
|
406.41M |
|
| Cash Flow Statement Financials | |
$-131.96M |
|
$-7.27M |
|
$40.53M |
|
$603.02M |
|
$509.16M |
|
$-93.87M |
|
$36.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.11 |
|
-- |
|
-- |
|
0.02 |
|
0.03 |
|
-48.04% |
|
-1297.85% |
|
|
EBIT Margin |
-1297.85% |
-- |
|
-1374.33% |
|
-1373.26% |
|
$-133.79M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
0.32 |
|
281.53 |
|
-21.68% |
|
-46.02% |
|
-15.51% |
|
-21.31% |
|
$2.30 |
|
$-0.33 |
|
$-0.33 |
|